DUBLIN--(BUSINESS WIRE)--The "Global Rare Disease Diagnostics Market: Focus on Genetic Diseases, Service Providers, Competitive Landscape, and Country - Analysis and Forecast, 2018-2025" report has been added to ResearchAndMarkets.com's offering.
The global rare disease diagnostics market was valued $45.18 billion in 2017 and is anticipated to reach $86.15 billion by 2025
The global rare disease diagnostics market (by disease type) is currently dominated by hematology and oncology segment. The contribution of hematology and oncology segment was valued $10.0 billion in 2017 and is expected to reach $20.5 billion by 2025, witnessing a CAGR of 9.35% during the forecast period.
Factors such as high incidence of rare diseases, presence of large numbers of research and development facilities for rare diseases, significant number of rare disease registries, high diagnosis rare of rare diseases in countries of North America, and extensive investments in different therapeutic areas are driving the growth of the North America rare disease diagnostics market. However, the Asia Pacific region is expected to register the highest CAGR of 9.22% during the forecast period 2018-2025.
Key Topics Covered:
Executive Summary
1 Market Overview
2 Market Dynamics
3 Competitive Landscape
4 Industry Insights
5 Global Rare Disease Diagnostics Market (by Disease Type)
6 Global Rare Disease Diagnostics Market (by Test Type)
7 Global Rare Disease Diagnostics Market (by Trait)
8 Global Rare Disease Diagnostics Market (by Age Group)
9 Global Rare Disease Diagnostics Market (by End User)
10 Global Rare Disease Diagnostics Market (by Region)
11 North America Rare Disease Diagnostics Market
12 Europe Rare Disease Diagnostics Market
13 Latin America Rare Disease Diagnostics Market
14 Asia Pacific Rare Disease Diagnostics Market
15 MEA Rare Disease Diagnostics Market
16 Company Profiles
- 23andMe, Inc.
- 3billion, Inc.
- BGI
- Centogene A.G.
- Eurofins Scientific
- GENEWIZ
- Illumina Inc.
- InDepth Genomics
- Laboratory Corporation of America
- Partek, Inc.
- PerkinElmer, Inc.
- Personal Genome Diagnostics, Inc.
- QIAGEN N.V.
- Retrophin, Inc.
- Strand Life Sciences Pvt Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/9zrdpd/global_rare?w=4
